- Home
- USEA vs APRE Comparison
USEA vs APRE Comparison
Compare USEA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- APRE
- Stock Information
- Founded
- USEA 2004
- APRE 2006
- Country
- USEA Greece
- APRE United States
- Employees
- USEA N/A
- APRE N/A
- Industry
- USEA Marine Transportation
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USEA Consumer Discretionary
- APRE Health Care
- Exchange
- USEA Nasdaq
- APRE Nasdaq
- Market Cap
- USEA 20.0M
- APRE 21.3M
- IPO Year
- USEA N/A
- APRE 2019
- Fundamental
- Price
- USEA $2.10
- APRE $3.25
- Analyst Decision
- USEA Strong Buy
- APRE Strong Buy
- Analyst Count
- USEA 1
- APRE 2
- Target Price
- USEA $6.00
- APRE $15.50
- AVG Volume (30 Days)
- USEA 40.8K
- APRE 15.3K
- Earning Date
- USEA 11-26-2024
- APRE 11-07-2024
- Dividend Yield
- USEA 14.29%
- APRE N/A
- EPS Growth
- USEA N/A
- APRE N/A
- EPS
- USEA 0.85
- APRE N/A
- Revenue
- USEA $46,276,000.00
- APRE $1,310,839.00
- Revenue This Year
- USEA $36.03
- APRE $116.72
- Revenue Next Year
- USEA $11.85
- APRE N/A
- P/E Ratio
- USEA $2.48
- APRE N/A
- Revenue Growth
- USEA 86.18
- APRE 130.31
- 52 Week Low
- USEA $2.05
- APRE $2.15
- 52 Week High
- USEA $3.00
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- USEA 31.62
- APRE 40.43
- Support Level
- USEA $2.23
- APRE $3.15
- Resistance Level
- USEA $2.18
- APRE $4.15
- Average True Range (ATR)
- USEA 0.10
- APRE 0.34
- MACD
- USEA -0.01
- APRE -0.12
- Stochastic Oscillator
- USEA 14.29
- APRE 13.97
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.